SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Economics of Follow-on Drug Research and Development
10 references·15 citing·37 second hop
The Economics of Follow-on Drug Research and Development (2004)The Economics of Follow-on Drug Research …The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001 (2003)The Impact of New Drug Launch…The free-market innovation machine: analyzing the growth miracle of capitalism (2002)The free-market innovation ma…Returns on Research and Development for 1990s New Drug Introductions (2002)Returns on Research and Devel…Risks in new drug development: Approval success rates for investigational drugs (2001)Risks in new drug development…New drug development in the United States from 1963 to 1999 (2001)New drug development in the U…Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS (2001)Are The Benefits Of Newer Dru…Strategic Pricing of New Pharmaceuticals (1998)Strategic Pricing of New Phar…Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)Scale, Scope, and Spillovers:…Barriers to New Competition (1957)Barriers to New CompetitionComparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019 (2023)Comparison of Research Spendi…Missing Novelty in Drug Development (2021)Missing Novelty in Drug Devel…Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development (2013)Innovation in the Pharmaceuti…An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011 (2013)An Improved Approach To Measu…The Competitive Implications of Certifications: The Effects of Scientific and Regulatory Certifications on Entries into New Technical Fields (2012)The Competitive Implications …Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model (2012)Nation-scale adoption of new …Mergers and innovation in the pharmaceutical industry (2012)Mergers and innovation in the…Getting Competition Down to a Science: The Effects of Technological Competition on Firms' Scientific Publications (2011)Getting Competition Down to a…Pharmaceutical Innovation (2010)Pharmaceutical InnovationPatents and Pharmaceutical R&D: Consolidating Private-Public Partnership Approach to Global Public Health Crises (2010)Patents and Pharmaceutical R&…Competitiveness in follow-on drug R&D: a race or imitation? (2010)Competitiveness in follow-on …Retail price regulation and innovation: Reference pricing in the pharmaceutical industry (2009)Retail price regulation and i…Competitive Response to Radical Product Innovations (2008)Competitive Response to Radic…Linking Pharmacogenetics-Based Diagnostics And Drugs For Personalized Medicine (2006)Linking Pharmacogenetics-Base…Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development??? (2005)Comment on ???The Economics o…Endogenous Technological Change (1989)ENDOGENOUS TECHNICAL CHANGE (1990)Endogenous Technological Change (1990)Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2003)Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry (2005)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Cost of innovation in the pharmaceutical industry (1991)Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances (2005)Economics of New Oncology Drug Development (2007)Deconstructing the Drug Development Process: The New Face of Innovation (2010)A New Product Growth for Model Consumer Durables (1969)A New Product Growth Model for Consumer Durables (1976)Health Care Financing Review (1980)Post-TRIPS Options for Access to Patented Medicines in Developing Nations (2002)Parallel imports and the pricing of pharmaceutical products: evidence from the European Union (2004)The Pharmaceutical Industry (2013)Is Technological Change In Medicine Worth It? (2001)Firm growth and R&D expenditure (2009)US biopharmaceutical finance and the sustainability of the biotech business model (2011)Small-Area Variations in the Use of Common Surgical Procedures: An International Comparison of New England, England, and Norway (1982)A Schumpeterian Model of the Product Life Cycle (1990)Hospitalizations and Deaths Among Adults With Cardiovascular Disease Who Underuse Medications Because of Cost (2010)The Free-Market Innovation Machine (2002)Firm Innovation in Emerging Markets: The Role of Finance, Governance, and Competition (2011)Environmental regulation and competitiveness: Empirical evidence on the Porter Hypothesis from European manufacturing sectors (2015)First-Mover Advantage: A Synthesis, Conceptual Framework, and Research Propositions (1992)The Social Structure of Entrepreneurial Activity: Geographic Concentration of Footwear Production in the United States, 1940–1989 (2000)Contestable Markets: An Uprising in the Theory of Industry Structure (2003)The Value of Improving the Productivity of the Drug Development Process (2002)The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry (2011)Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development (2012)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)The Burden of Knowledge and the “Death of the Renaissance Man”: Is Innovation Getting Harder? (2008)Fifty Years of Empirical Studies of Innovative Activity and Performance (2010)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 1957Barriers to New Competition2,721 cited
  • 1996Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery1,389 cited
  • 2002The free-market innovation machine: analyzing the growth miracle of capitalism1,195 cited
  • 2001Risks in new drug development: Approval success rates for investigational drugs450 cited
  • 2002Returns on Research and Development for 1990s New Drug Introductions311 cited
  • 2001New drug development in the United States from 1963 to 1999251 cited
  • 1998Strategic Pricing of New Pharmaceuticals249 cited
  • 2001Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS214 cited
  • 2003The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001200 cited

Cited by

  • 2013An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011138 cited
  • 2012Mergers and innovation in the pharmaceutical industry114 cited
  • 2008Competitive Response to Radical Product Innovations108 cited
  • 2021Missing Novelty in Drug Development106 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2005
Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development???
103 cited
  • 2011Getting Competition Down to a Science: The Effects of Technological Competition on Firms' Scientific Publications100 cited
  • 2013Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development98 cited
  • 2010Competitiveness in follow-on drug R&D: a race or imitation?95 cited
  • 2012The Competitive Implications of Certifications: The Effects of Scientific and Regulatory Certifications on Entries into New Technical Fields87 cited
  • 2009Retail price regulation and innovation: Reference pricing in the pharmaceutical industry71 cited
  • 2010Pharmaceutical Innovation68 cited
  • 2023Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-201961 cited
  • 2006Linking Pharmacogenetics-Based Diagnostics And Drugs For Personalized Medicine61 cited
  • 2012Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model32 cited
  • 2010Patents and Pharmaceutical R&D: Consolidating Private-Public Partnership Approach to Global Public Health Crises20 cited